Introduction
The "Test-and-Treat" strategy is a cornerstone of modern HIV prevention, positing that universal testing followed by immediate antiretroviral therapy (ART) can significantly curtail community-level transmission. The success of this approach hinges on identifying and treating individuals during their most infectious periods—specifically when plasma HIV-1 RNA levels (viral loads) are high.
While HIV-1 Subtype B is well-documented in Western contexts, Subtype C—the most prevalent global subtype and the dominant strain in Southern Africa—has less characterized viral load dynamics. This study analyzes HIV-1 Subtype C viral load distributions in Botswana to optimize the timing and frequency of "Test-and-Treat" interventions.
Methods
Researchers conducted a retrospective analysis using data from the Botswana–Harvard AIDS Institute Partnership, focusing on two primary objectives:
- Cross-sectional Analysis: Baseline viral loads were assessed for 4,348 drug-naïve individuals across seven cohorts, ranging from the general population to those initiating combination ART (cART).
- Longitudinal Analysis: Data from 42 "seroconverters" (individuals with estimated infection dates) were used to model viral load progression over time using cubic smoothing splines and Kaplan-Meier estimates.
The study defined "high viral load" as $\ge$ 50,000 copies/ml (4.7 $log_{10}$). Simulations were performed to evaluate the efficacy of 6-month versus 12-month testing intervals in identifying these high-viremia windows.
Datasets
The analysis utilized seven distinct cohorts from Botswana:
- General Population/Natural History: Botsogo and Dikotlana studies.
- Mother-to-Child Transmission (MTCT): Mashi and Mma Bana studies.
- Treatment-Initiating (cART): Tshepo, Mashi Plus, and Bomolemo studies.
- Primary Infection: The Tshedimoso study provided longitudinal data for the seroconverter group.
Results
Viral Load Distribution and Heterogeneity
The study found a significant gap in median viral loads between populations. In general population cohorts, median levels ranged from 4.1 to 4.2 $log_{10}$, with 24%–28% of individuals exhibiting high viral loads. In contrast, treatment-seeking cohorts showed median levels of 5.1 to 5.3 $log_{10}$, with 65%–83% of individuals exceeding the 50,000 copies/ml threshold. Notably, men in the general population cohorts tended to have higher viral loads than women.
Duration of High Infectivity
Longitudinal analysis revealed a "high-transmitter" phenotype: approximately 33% (95% CI: 20%–50%) of individuals maintain a viral load $\ge$ 50,000 copies/ml for at least 180 days post-seroconversion. The median duration of this highly infectious state was 350 days (IQR: 269–428).
Impact of Testing Intervals
Modeling suggests that a 6-month testing interval is a critical "sweet spot." This frequency could identify all individuals maintaining high viral loads and, assuming immediate treatment initiation, reduce the period of high transmissibility by 77% (95% CI: 71%–82%). In comparison, a 12-month interval was significantly less effective, reducing the high-transmissibility window by only 56%.
Discussion and Implications
These findings suggest that a subset of the population contributes disproportionately to the HIV epidemic by maintaining high viral loads for extended periods. Targeting these individuals through frequent, repeated testing could be a highly effective public health strategy.
Limitations
The study's longitudinal findings are based on a relatively small sample of 42 seroconverters. Furthermore, the model assumes immediate treatment initiation and 100% efficacy in stopping transmission, which may not account for real-world barriers such as drug resistance or suboptimal adherence. Future research should also investigate behavioral drivers of transmission and potential gender-based differences in viral dynamics.
Summary updated